- Home
- NUKK vs MGNX Comparison
NUKK vs MGNX Comparison
Compare NUKK & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- MGNX
- Stock Information
- Founded
- NUKK 2013
- MGNX 2000
- Country
- NUKK United States
- MGNX United States
- Employees
- NUKK N/A
- MGNX N/A
- Industry
- NUKK Blank Checks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- MGNX Health Care
- Exchange
- NUKK Nasdaq
- MGNX Nasdaq
- Market Cap
- NUKK 100.0M
- MGNX 94.9M
- IPO Year
- NUKK N/A
- MGNX 2013
- Fundamental
- Price
- NUKK $5.70
- MGNX $1.50
- Analyst Decision
- NUKK
- MGNX Hold
- Analyst Count
- NUKK 0
- MGNX 5
- Target Price
- NUKK N/A
- MGNX $3.20
- AVG Volume (30 Days)
- NUKK 1.5M
- MGNX 887.6K
- Earning Date
- NUKK 11-14-2025
- MGNX 11-12-2025
- Dividend Yield
- NUKK N/A
- MGNX N/A
- EPS Growth
- NUKK N/A
- MGNX N/A
- EPS
- NUKK N/A
- MGNX N/A
- Revenue
- NUKK N/A
- MGNX $127,626,000.00
- Revenue This Year
- NUKK N/A
- MGNX N/A
- Revenue Next Year
- NUKK N/A
- MGNX N/A
- P/E Ratio
- NUKK N/A
- MGNX N/A
- Revenue Growth
- NUKK N/A
- MGNX N/A
- 52 Week Low
- NUKK $1.34
- MGNX $0.99
- 52 Week High
- NUKK $78.32
- MGNX $3.77
- Technical
- Relative Strength Index (RSI)
- NUKK 48.01
- MGNX 46.92
- Support Level
- NUKK $4.05
- MGNX $1.33
- Resistance Level
- NUKK $6.99
- MGNX $1.64
- Average True Range (ATR)
- NUKK 0.78
- MGNX 0.11
- MACD
- NUKK 0.13
- MGNX 0.00
- Stochastic Oscillator
- NUKK 56.44
- MGNX 42.70
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.